FcγRIIb expression in early stage chronic lymphocytic leukemia

Rosa Bosch, Alba Mora, Eva Puy Vicente, Gerardo Ferrer, Sonia Jansà, Rajendra Damle, Sergey Gorlatov, Kanti Rai, Emili Montserrat, Josep Nomdedeu, Marta Pratcorona, Laura Blanco, Silvana Saavedra, Ana Garrido, Albert Esquirol, Irene Garcia, Miquel Granell, Rodrigo Martino, Julio Delgado, Jorge SierraNicholas Chiorazzi, Carol Moreno

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


© 2017 Informa UK Limited, trading as Taylor & Francis Group. In normal B-cells, B-cell antigen receptor (BCR) signaling can be negatively regulated by the low-affinity receptor FcγRIIb (CD32b). To better understand the role of FcγRIIb in chronic lymphocytic leukemia (CLL), we correlated its expression on 155 samples from newly-diagnosed Binet A patients with clinical characteristics and outcome. FcγRIIb expression was similar in normal B-cells and leukemic cells, this being heterogenous among patients and within CLL clones. FcγRIIb expression did not correlate with well known prognostic markers [disease stage, serum beta-2 microglobulin (B2M), IGHV mutational status, expression of ZAP-70 and CD38, and cytogenetics] except for a weak concordance with CD49d. Moreover, patients with low FcγRIIb expression (69/155, 44.5%) required therapy earlier than those with high FcγRIIb expression (86/155, 55.5%) (median 151.4 months vs. not reached; p=.071). These results encourage further investigation on the role of FcγRIIb in CLL biology and prognostic significance in larger series of patients.
Original languageEnglish
Pages (from-to)2642-2648
JournalLeukemia and Lymphoma
Issue number11
Publication statusPublished - 2 Nov 2017


  • B-cell activation
  • B-cell receptor
  • Chronic lymphocytic leukemia
  • FcγRIIb
  • treatment-free survival


Dive into the research topics of 'FcγRIIb expression in early stage chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this